Navigation Links
Discovery Labs Receives US Patent for Method to Promote Mucus Clearance with Pulmonary Surfactant
Date:7/18/2012

WARRINGTON, Pa., July 18, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced it has received a patent issued by the United States Patent and Trademark Office (USPTO) entitled "Pulmonary Surfactant Formulations and Methods for Promoting Mucus Clearance."  The claims of the patent (U.S. Patent Number 8,221,772) provide coverage for a method for promoting mucus clearance in a patient with a pulmonary condition characterized by excessive mucus secretion or impaired mucus clearance such as cystic fibrosis (CF), bronchiectasis, ciliary diskinesia, chronic obstructive pulmonary disease (COPD), and sinusitis.  The patent term expires in September 2027.

"This patent enhances Discovery Labs' patent portfolio by providing protection in the area of pulmonary conditions characterized by impaired mucus clearance," said W. Thomas Amick, Chairman of the Board and Chief Executive Officer of Discovery Labs.   "Combined with Discovery Labs' proprietary aerosolization technologies, our KL4 surfactant may provide a new opportunity to develop treatments to address a number of debilitating respiratory disorders where unmet needs still persist." 

In addition to this patent, Discovery Labs also has the benefit of certain regulatory designations, including U.S. and EU Orphan Designations for the treatment of CF with KL4 surfactant, which potentially strengthen the company's exclusivity position for this indication.

ABOUT DISCOVERY LABS
Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to create life-saving products for critical care patients with respiratory disease and improve the standard of care for pulmonary medicine. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide- containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized and aerosolized formulations. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient, targeted upper-respiratory or alveolar delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs believes that its proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.discoverylabs.com.

Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Examples of such risks and uncertainties, including those related to Discovery Labs' efforts to secure exclusivity protections for its drug and medical device products through patents and regulatory designations, are described in Discovery Labs' filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Any forward-looking statement in this release speaks only as of the date on which it is made. Discovery Labs assumes no obligation to update or revise any forward-looking statements.


'/>"/>
SOURCE Discovery Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
2. Global Information, Inc. Announces New Market Forecasts For Drug Discovery Industry as it Emerges from Recession
3. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
4. AMRI Further Expands Discovery Capabilities in India
5. Drug Discovery Technologies Market Soars to $79 billion by 2017, Driven by Innovations in Pipeline and Tools Development
6. Aethlon Medical (AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis
7. Dr. Paul Karila Appointed Head of Discovery Services at Cellectricon AB
8. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
9. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
10. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
11. TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market ... companies have joined forces, resulting in the founding of Pharma To ... Pharma To Market are pleased to announce their expansion into ... in Singapore . The company are delighted to ... Co-Director of the Singapore based entity. Joelle ...
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... STOCKHOLM , Feb 24, 2017 ... Nomination Committee,s proposal for a new Board of Directors ... Meeting. The 2016-2017 Nomination Committee comprises representatives of the ... third quarter of 2016 who have accepted a seat ... Board. The composition of the 2016-2017 Nomination Committee was ...
Breaking Medicine Technology:
(Date:2/24/2017)... CA (PRWEB) , ... February 24, 2017 , ... ... for qualifying into the Senior International Elite division on February 12th. Ms. ... Around divisions at the elite qualifier competition held in Las Vegas, Nevada. Frida ...
(Date:2/23/2017)... ... 2017 , ... The 89th Academy Awards will be celebrated this weekend, which ... Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to ... the Center for American Progress (CAP), for its report, Lessons From State Performance on ...
(Date:2/23/2017)... ... ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will be appearing ... which will begin airing on February 24, 2017. The show chronicles the weight loss ... television series, “Here Comes Honey Boo Boo.” The earlier series from TLC lasted for ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... it will soon begin franchising throughout the U.S. starting this spring. Current Meditation ... the practice of meditation mainstream. Current Meditation will be the first meditation concept ...
Breaking Medicine News(10 mins):